A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02032277
Recruitment Status : Active, not recruiting
First Posted : January 10, 2014
Last Update Posted : May 10, 2018
German Breast Group
NSABP Foundation Inc
Grupo Español de Investigación del Cáncer de Mama
US Oncology Research
Alliance for Clinical Trials in Oncology
Information provided by (Responsible Party):